Published Date: 10 Mar 2023
United States: The US research team recommended using a different agent to enhance the Doppler profile for more accurate measurements.
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]
Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.
Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.
5 Rheumatology Headlines You Missed in December 2025
Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation
1.
Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.
2.
Chronic pain and poor sleep are troublesome bed partners.
3.
In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.
4.
Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?
5.
combating racial discrimination in next-generation breast cancer screening.
1.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
2.
A New Hope: How Procarbazine is Revolutionizing Cancer Treatment
3.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
4.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
3.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
5.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation